Delivery Order SPE2DR25D3014-SPE2DR26FP1EQ
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,648.59 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector pens, with an ultimate completion date of September 12, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The award reflects AmerisourceBergen's role as a critical pharmaceutical distributor supporting federal medical procurement, particularly for military and veteran healthcare systems. The place of...
- The Defense Logistics Agency awarded a $42,441.39 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injector pens on November 3, 2025, with completion scheduled for November 4, 2025. This competitively awarded, firm fixed-price contract represents a single delivery order for a specialty pharmaceutical product used in cardiovascular disease management. The contract is performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania, leveraging...
- The Defense Logistics Agency awarded a $34,728.60 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector pens, with an ultimate completion date of October 27, 2025. This competitive award, issued on October 24, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The delivery will be performed at...
- The Defense Logistics Agency awarded a delivery order valued at $1,041.42 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/ml SureClick auto-injector pens, with an ultimate completion date of August 5, 2025. This non-set-aside, competitively awarded contract employs firm fixed price terms and represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The product will be delivered to the company's facility in...
- The Defense Logistics Agency awarded a delivery order valued at $91,225.90 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/ml SureClick auto-injector pens. This firm fixed-price delivery order, issued on September 18, 2025, with an ultimate completion date of September 19, 2025, represents a non-competitive award under an existing contract vehicle. The work will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility, the company's corporate headquarters and a...
- The Defense Logistics Agency awarded a delivery order valued at $1,325.96 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector pens. This competitive award, issued on November 20, 2025, with an ultimate completion date of November 21, 2025, represents a firm fixed price delivery order with no set-aside designation. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under the company's...
- The Defense Logistics Agency awarded a $4,990.71 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector pens, with an ultimate completion date of December 9, 2025. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and running through December 2026. The pharmaceutical product will be delivered to...
- The Defense Logistics Agency awarded a delivery order valued at $16,968.74 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector pens, with an ultimate completion date of November 4, 2025. This non-competitive delivery order utilizes firm fixed pricing and represents a single transaction under AmerisourceBergen's larger contract vehicle with DLA. The product will be delivered to AmerisourceBergen's corporate headquarters location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $34,197.25 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector pens, with an ultimate completion date of August 22, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, with particular focus on supporting military and veteran...
- The Defense Logistics Agency awarded a $9,272.65 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injector pens, with an ultimate completion date of September 4, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and running through December 2026. The pharmaceutical product will be delivered to...
- SPE2DR25D3014Indefinite Delivery Contract
- SPE2DR25D3014-SPE2DR26FP1EQDelivery Order
The Defense Logistics Agency awarded a $3,406.63 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector pens, with an ultimate completion date of December 3, 2025. This competitively awarded contract, issued with no set-aside designation, represents a single delivery order fulfillment under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal military and veteran healthcare systems, with performance occurring at the contractor's corporate office location in Conshohocken, PA. This delivery order falls under AmerisourceBergen's comprehensive $999,999,999 IDC with DLA Troop Support Medical (contract SPE2DX), which extends through December 2026 and provides global pharmaceutical support to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. Repatha is a PCSK9 inhibitor used for cholesterol management in patients with cardiovascular disease, representing the type of specialty medication included in the contractor's expansive pharmaceutical supply portfolio. The award demonstrates AmerisourceBergen's ongoing role as a key vendor within the DLA's medical supply chain for delivering critical therapeutic medications to military healthcare programs worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.4k | 12/1/25 |